Hantz Financial Services Inc. raised its stake in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 46.9% during the 4th quarter, Holdings Channel reports. The fund owned 122,860 shares of the company’s stock after purchasing an additional 39,244 shares during the period. Hantz Financial Services Inc.’s holdings in Astrazeneca were worth $21,562,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Cibc World Market Inc. boosted its position in shares of Astrazeneca by 21.5% in the 3rd quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock worth $4,942,000 after purchasing an additional 11,398 shares in the last quarter. TD Asset Management Inc boosted its position in shares of Astrazeneca by 20.0% in the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after purchasing an additional 181,273 shares in the last quarter. Y Intercept Hong Kong Ltd boosted its position in shares of Astrazeneca by 111.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company’s stock worth $5,113,000 after purchasing an additional 35,148 shares in the last quarter. AMG National Trust Bank boosted its position in shares of Astrazeneca by 20.4% in the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock worth $3,298,000 after purchasing an additional 7,289 shares in the last quarter. Finally, Assetmark Inc. boosted its position in shares of Astrazeneca by 6.5% in the 3rd quarter. Assetmark Inc. now owns 310,383 shares of the company’s stock worth $23,813,000 after purchasing an additional 19,020 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the company. Barclays raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Citigroup initiated coverage on Astrazeneca in a research report on Tuesday, January 27th. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research report on Thursday. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Astrazeneca has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.
Astrazeneca Stock Performance
Shares of AZN opened at $187.24 on Monday. The stock has a 50-day moving average of $191.66 and a two-hundred day moving average of $183.08. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The stock has a market cap of $290.39 billion, a P/E ratio of 28.11, a P/E/G ratio of 1.54 and a beta of 0.26.
Astrazeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. As a group, research analysts predict that Astrazeneca Plc will post 9.62 EPS for the current year.
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
- Five stocks we like better than Astrazeneca
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
